What is the recommended dosing regimen of nirmatrelvir (with ritonavir) for an elderly patient (≥65 years) with COVID‑19 and normal renal function (eGFR ≥60 mL/min)?

Nirmatrelvir Dosing for Elderly Patients with Normal Renal Function

For an elderly patient (≥65 years) with COVID-19 and normal renal function (eGFR ≥60 mL/min), administer nirmatrelvir 300 mg (two 150 mg tablets) with ritonavir 100 mg (one 100 mg tablet) orally twice daily for 5 days—no dose adjustment is needed based on age alone when renal function is preserved. 1

Standard Dosing Regimen

The FDA-approved dosing is straightforward for patients with preserved kidney function:

• Dose: Nirmatrelvir 300 mg + ritonavir 100 mg (total of 3 tablets)
• Frequency: Twice daily (morning and bedtime)
• Duration: 5 days
• Timing: Initiate within 5 days of symptom onset
• Administration: Can be taken with or without food; tablets must be swallowed whole 1

No dosage adjustment is required for patients with eGFR ≥60 mL/min, including elderly patients, as long as renal function remains normal 1. Age itself does not necessitate dose modification.

Clinical Context for Elderly Patients

The American College of Physicians supports using nirmatrelvir-ritonavir for symptomatic patients with confirmed mild-to-moderate COVID-19 who are at high risk for progression to severe disease 2. Elderly patients (≥65 years) inherently fall into this high-risk category.

Evidence demonstrates that nirmatrelvir-ritonavir reduces hospitalization or death by approximately 89% when initiated within 5 days of symptom onset 3. In elderly populations specifically, the treatment has shown effectiveness with low rates of adverse events (5.9% in one study of patients with median age 80 years) 4.

Critical Monitoring Considerations for Elderly Patients

Drug-Drug Interactions (DDIs)

This is the primary concern in elderly patients, who typically take multiple medications:

• Approximately 71% of elderly patients on nirmatrelvir-ritonavir have potential pharmacokinetic DDIs 5
• Ritonavir is a potent CYP3A4 inhibitor and causes interactions with numerous common medications
• Before prescribing, review all current medications for contraindicated drugs (e.g., amiodarone, dronedarone, colchicine in renal/hepatic impairment, statins metabolized by CYP3A4) 1
• Consider temporary discontinuation or dose adjustment of interacting medications during the 5-day treatment course

Renal Function Monitoring

While your patient has normal renal function now, verify eGFR before prescribing because:

• Studies show 65% of elderly patients with renal impairment receive inadequate dose adjustments 5
• If eGFR is 30-60 mL/min (moderate impairment): reduce to 150 mg nirmatrelvir + 100 mg ritonavir twice daily 1
• If eGFR <30 mL/min (severe impairment): 300 mg nirmatrelvir + 100 mg ritonavir on day 1, then 150 mg + 100 mg once daily for days 2-5 1

Common Pitfalls to Avoid

1. Failing to screen for drug interactions: This is the most common error in elderly patients. Use interaction checkers before prescribing.

2. Not verifying actual renal function: Don't assume normal function based on age alone—calculate eGFR.

3. Delayed initiation: The 5-day window from symptom onset is critical for efficacy. Don't delay while awaiting specialist consultation if the patient meets criteria.

4. Incomplete treatment course: Ensure patients complete all 5 days even if symptoms improve 1.

Missed Dose Instructions

• If <8 hours late: take immediately and resume normal schedule
• If >8 hours late: skip the missed dose, take next dose at regular time
• Never double doses 1

Safety Profile in Elderly

The treatment is generally well-tolerated in elderly patients. Most common adverse effects are dysgeusia (altered taste, 5.6%) and diarrhea (3.1%), which are typically mild 3. Serious adverse events are uncommon (2.6% in elderly cohorts) 4, 6.